Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms

Targeting tyrosine kinases represents a highly specific treatment approach for different malignancies. This also includes non-Hodgkin lymphoma since it is well known that these enzymes are frequently involved in the lymphomagenesis. Hereby, tyrosine kinases might either be dysregulated intrinsically...

Full description

Saved in:
Bibliographic Details
Published in:Biomarker insights 2015-01, Vol.10s3
Main Authors: Nadine Kutsch, Reinhard Marks, Richard Ratei, Thomas K. Held, Martin Schmidt-Hieber
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue
container_start_page
container_title Biomarker insights
container_volume 10s3
creator Nadine Kutsch
Reinhard Marks
Richard Ratei
Thomas K. Held
Martin Schmidt-Hieber
description Targeting tyrosine kinases represents a highly specific treatment approach for different malignancies. This also includes non-Hodgkin lymphoma since it is well known that these enzymes are frequently involved in the lymphomagenesis. Hereby, tyrosine kinases might either be dysregulated intrinsically or be activated within signal transduction pathways leading to tumor survival and growth. Among others, Bruton's tyrosine kinase (Btk) is of particular interest as a potential therapeutic target. Btk is stimulated by B-cell receptor signaling and activates different transcription factors such as nuclear factor K B. The Btk inhibitor ibrutinib has been approved for the treatment of chronic lymphocytic leukemia and mantle-cell lymphoma recently. Numerous clinical trials evaluating this agent in different combinations (eg, with rituximab or classical chemotherapeutic agents) as a treatment option for aggressive and indolent lymphoma are under way. Here, we summarize the role of tyrosine kinase inhibitors in the treatment of indolent and other non-Hodgkin lymphomas (eg, mantle-cell lymphoma).
doi_str_mv 10.4137/BMI.S22434
format article
fullrecord <record><control><sourceid>doaj</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_ff8297a4350c49f6a000f1a87e7f9c19</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_ff8297a4350c49f6a000f1a87e7f9c19</doaj_id><sourcerecordid>oai_doaj_org_article_ff8297a4350c49f6a000f1a87e7f9c19</sourcerecordid><originalsourceid>FETCH-doaj_primary_oai_doaj_org_article_ff8297a4350c49f6a000f1a87e7f9c193</originalsourceid><addsrcrecordid>eNqtjM1KAzEURoMgWH82PsF9galJJm0m2xbFQarSdh-uMzc2JU1KEhd9e4v4CF19nMPhY-xR8KkSrX5arPrpRkrVqis2EULrRmphbthtKXvOZ_NO8gn7XKdAkBxsTzkVHwnefMRC0Med__I15QI-nmk8d7ECxhE-6o4yrLD-ZIJFs6QQ4J3SMWA5lHt27TAUevjfO9a_PG-Xr82YcG-P2R8wn2xCb_9Eyt8Wc_VDIOtcJ41G1c74oIybI-fcCew0aWcGYdpLfv0CweFbVg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms</title><source>SAGE Open Access</source><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Nadine Kutsch ; Reinhard Marks ; Richard Ratei ; Thomas K. Held ; Martin Schmidt-Hieber</creator><creatorcontrib>Nadine Kutsch ; Reinhard Marks ; Richard Ratei ; Thomas K. Held ; Martin Schmidt-Hieber</creatorcontrib><description>Targeting tyrosine kinases represents a highly specific treatment approach for different malignancies. This also includes non-Hodgkin lymphoma since it is well known that these enzymes are frequently involved in the lymphomagenesis. Hereby, tyrosine kinases might either be dysregulated intrinsically or be activated within signal transduction pathways leading to tumor survival and growth. Among others, Bruton's tyrosine kinase (Btk) is of particular interest as a potential therapeutic target. Btk is stimulated by B-cell receptor signaling and activates different transcription factors such as nuclear factor K B. The Btk inhibitor ibrutinib has been approved for the treatment of chronic lymphocytic leukemia and mantle-cell lymphoma recently. Numerous clinical trials evaluating this agent in different combinations (eg, with rituximab or classical chemotherapeutic agents) as a treatment option for aggressive and indolent lymphoma are under way. Here, we summarize the role of tyrosine kinase inhibitors in the treatment of indolent and other non-Hodgkin lymphomas (eg, mantle-cell lymphoma).</description><identifier>EISSN: 1177-2719</identifier><identifier>DOI: 10.4137/BMI.S22434</identifier><language>eng</language><publisher>SAGE Publishing</publisher><ispartof>Biomarker insights, 2015-01, Vol.10s3</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Nadine Kutsch</creatorcontrib><creatorcontrib>Reinhard Marks</creatorcontrib><creatorcontrib>Richard Ratei</creatorcontrib><creatorcontrib>Thomas K. Held</creatorcontrib><creatorcontrib>Martin Schmidt-Hieber</creatorcontrib><title>Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms</title><title>Biomarker insights</title><description>Targeting tyrosine kinases represents a highly specific treatment approach for different malignancies. This also includes non-Hodgkin lymphoma since it is well known that these enzymes are frequently involved in the lymphomagenesis. Hereby, tyrosine kinases might either be dysregulated intrinsically or be activated within signal transduction pathways leading to tumor survival and growth. Among others, Bruton's tyrosine kinase (Btk) is of particular interest as a potential therapeutic target. Btk is stimulated by B-cell receptor signaling and activates different transcription factors such as nuclear factor K B. The Btk inhibitor ibrutinib has been approved for the treatment of chronic lymphocytic leukemia and mantle-cell lymphoma recently. Numerous clinical trials evaluating this agent in different combinations (eg, with rituximab or classical chemotherapeutic agents) as a treatment option for aggressive and indolent lymphoma are under way. Here, we summarize the role of tyrosine kinase inhibitors in the treatment of indolent and other non-Hodgkin lymphomas (eg, mantle-cell lymphoma).</description><issn>1177-2719</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNqtjM1KAzEURoMgWH82PsF9galJJm0m2xbFQarSdh-uMzc2JU1KEhd9e4v4CF19nMPhY-xR8KkSrX5arPrpRkrVqis2EULrRmphbthtKXvOZ_NO8gn7XKdAkBxsTzkVHwnefMRC0Med__I15QI-nmk8d7ECxhE-6o4yrLD-ZIJFs6QQ4J3SMWA5lHt27TAUevjfO9a_PG-Xr82YcG-P2R8wn2xCb_9Eyt8Wc_VDIOtcJ41G1c74oIybI-fcCew0aWcGYdpLfv0CweFbVg</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Nadine Kutsch</creator><creator>Reinhard Marks</creator><creator>Richard Ratei</creator><creator>Thomas K. Held</creator><creator>Martin Schmidt-Hieber</creator><general>SAGE Publishing</general><scope>DOA</scope></search><sort><creationdate>20150101</creationdate><title>Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms</title><author>Nadine Kutsch ; Reinhard Marks ; Richard Ratei ; Thomas K. Held ; Martin Schmidt-Hieber</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-doaj_primary_oai_doaj_org_article_ff8297a4350c49f6a000f1a87e7f9c193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nadine Kutsch</creatorcontrib><creatorcontrib>Reinhard Marks</creatorcontrib><creatorcontrib>Richard Ratei</creatorcontrib><creatorcontrib>Thomas K. Held</creatorcontrib><creatorcontrib>Martin Schmidt-Hieber</creatorcontrib><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Biomarker insights</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nadine Kutsch</au><au>Reinhard Marks</au><au>Richard Ratei</au><au>Thomas K. Held</au><au>Martin Schmidt-Hieber</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms</atitle><jtitle>Biomarker insights</jtitle><date>2015-01-01</date><risdate>2015</risdate><volume>10s3</volume><eissn>1177-2719</eissn><abstract>Targeting tyrosine kinases represents a highly specific treatment approach for different malignancies. This also includes non-Hodgkin lymphoma since it is well known that these enzymes are frequently involved in the lymphomagenesis. Hereby, tyrosine kinases might either be dysregulated intrinsically or be activated within signal transduction pathways leading to tumor survival and growth. Among others, Bruton's tyrosine kinase (Btk) is of particular interest as a potential therapeutic target. Btk is stimulated by B-cell receptor signaling and activates different transcription factors such as nuclear factor K B. The Btk inhibitor ibrutinib has been approved for the treatment of chronic lymphocytic leukemia and mantle-cell lymphoma recently. Numerous clinical trials evaluating this agent in different combinations (eg, with rituximab or classical chemotherapeutic agents) as a treatment option for aggressive and indolent lymphoma are under way. Here, we summarize the role of tyrosine kinase inhibitors in the treatment of indolent and other non-Hodgkin lymphomas (eg, mantle-cell lymphoma).</abstract><pub>SAGE Publishing</pub><doi>10.4137/BMI.S22434</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier EISSN: 1177-2719
ispartof Biomarker insights, 2015-01, Vol.10s3
issn 1177-2719
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_ff8297a4350c49f6a000f1a87e7f9c19
source SAGE Open Access; Publicly Available Content Database; PubMed Central
title Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T23%3A26%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-doaj&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20Tyrosine%20Kinase%20Inhibitors%20in%20Indolent%20and%20Other%20Mature%20B-Cell%20Neoplasms&rft.jtitle=Biomarker%20insights&rft.au=Nadine%20Kutsch&rft.date=2015-01-01&rft.volume=10s3&rft.eissn=1177-2719&rft_id=info:doi/10.4137/BMI.S22434&rft_dat=%3Cdoaj%3Eoai_doaj_org_article_ff8297a4350c49f6a000f1a87e7f9c19%3C/doaj%3E%3Cgrp_id%3Ecdi_FETCH-doaj_primary_oai_doaj_org_article_ff8297a4350c49f6a000f1a87e7f9c193%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true